Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy.
about
Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.The proteasome and proteasome inhibitors in multiple myeloma.Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma.A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility.
P2860
Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Comparative proteomic profilin ...... e to bortezomib-based therapy.
@en
Comparative proteomic profilin ...... e to bortezomib-based therapy.
@nl
type
label
Comparative proteomic profilin ...... e to bortezomib-based therapy.
@en
Comparative proteomic profilin ...... e to bortezomib-based therapy.
@nl
prefLabel
Comparative proteomic profilin ...... e to bortezomib-based therapy.
@en
Comparative proteomic profilin ...... e to bortezomib-based therapy.
@nl
P2093
P2860
P50
P356
P1433
P1476
Comparative proteomic profilin ...... e to bortezomib-based therapy.
@en
P2093
Adam Nowicki
Andrzej Jakubowiak
Anna Przybylowicz-Chalecka
Blazej Ratajczak
Dominik Dytfeld
Elzbieta Czechowska
Joanna Czerwinska-Rybak
Katarzyna Brzezniakiewicz
Katarzyna Tusznio
Lidia Usnarska-Zubkiewicz
P2860
P304
56726-56736
P356
10.18632/ONCOTARGET.11059
P407
P577
2016-08-04T00:00:00Z